<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METRONIDAZOLE- metronidazoleÂ gelÂ </strong><br>Oceanside Pharmaceuticals<br></p></div>
<h1><span class="Bold">Metronidazole Vaginal Gel, 0.75%</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FOR INTRAVAGINAL USE ONLY<br>NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Metronidazole Vaginal Gel is the intravaginal dosage form of the synthetic antibacterial agent, metronidazole, USP at a concentration of 0.75%. Metronidazole is a member of the imidazole class of antibacterial agents and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is a 2-methyl-5-nitroimidazole-1-ethanol. It has a chemical formula of C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span>, a molecular weight of 171.16, and has the following structure:</p>
<div class="Figure"><img alt="61eb770c-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-1.jpg"></div>
<p>Metronidazole Vaginal Gel is a gelled, purified water solution, containing metronidazole at a concentration of 7.5 mg/g (0.75%). The gel is formulated at pH 4.0. The gel also contains carbomer 934P, edetate disodium, methylparaben, propylparaben, propylene glycol, and sodium hydroxide.</p>
<p>Each applicator full of 5 grams of vaginal gel contains approximately 37.5 mg of metronidazole.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First"><span class="Bold">Normal Subjects:</span></p>
<p>Following a single, intravaginal 5 gram dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole) to 12 normal subjects, a mean maximum serum metronidazole concentration of 237 ng/mL was reported (range: 152 to 368 ng/mL). This is approximately 2% of the mean maximum serum metronidazole concentration reported in the same subjects administered a single, oral 500 mg dose of metronidazole (mean C<span class="Sub">max</span> = 12,785 ng/mL, range: 10,013 to 17,400 ng/mL). These peak concentrations were obtained in 6 to 12 hours after dosing with metronidazole vaginal gel and 1 to 3 hours after dosing with oral metronidazole.</p>
<p>The extent of exposure [area under the curve (AUC)] of metronidazole, when administered as a single intravaginal 5 gram dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole), was approximately 4% of the AUC of a single oral 500 mg dose of metronidazole (4977 ng-hr/mL and approximately 125,000 ng-hr/mL, respectively).</p>
<p>Dose-adjusted comparisons of AUCs demonstrated that, on a mg to mg comparison basis, the absorption of metronidazole, when administered vaginally, was approximately half that of an equivalent oral dosage.</p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span>:</span></p>
<p>Following single and multiple 5 gram doses of metronidazole vaginal gel to 4 patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, a mean maximum serum metronidazole concentration of 214 ng/mL on day 1 and 294 ng/mL (range: 228 to 349 ng/mL) on day five were reported. Steady state metronidazole serum concentrations following oral dosages of 400 to 500 mg BID have been reported to range from 6,000 to 20,000 ng/mL.</p>
<p><span class="Bold">Microbiology:</span></p>
<p>The intracellular targets of action of metronidazole on anaerobes are largely unknown. The 5-nitro group of metronidazole is reduced by metabolically active anaerobes, and studies have demonstrated that the reduced form of the drug interacts with bacterial DNA. However, it is not clear whether interaction with DNA alone is an important component in the bactericidal action of metronidazole on anaerobic organisms.</p>
<p>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. (See <span class="Bold"><a href="#s3">INDICATIONS AND USAGE</a></span>.)</p>
<p>Standard methodology for the susceptibility testing of the potential <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> pathogens, <span class="Italics">Gardnerella vaginalis</span>, <span class="Italics">Mobiluncus </span>spp., and <span class="Italics">Mycoplasma hominis</span>, has not been defined. Nonetheless, metronidazole is an antimicrobial agent active <span class="Italics">in vitro </span>against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<p><span class="Italics">	Bacteroides </span>spp.</p>
<p><span class="Italics">Gardnerella vaginalis</span></p>
<p><span class="Italics">	Mobiluncus </span>spp.</p>
<p><span class="Italics">Peptostreptococcus </span>spp.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Metronidazole Vaginal Gel is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> (formerly referred to as <span class="Italics">Haemophilus </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Gardnerella </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, nonspecific <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Corynebacterium </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, or anaerobic vaginosis).</p>
<p><span class="Bold">NOTE:	</span>For purposes of this indication, a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> is usually defined by the presence 	of a homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a â€œfishyâ€? amine odor 	when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gramâ€™s 	stain results consistent with a diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> include (a) markedly reduced or absent 	<span class="Italics">Lactobacillus </span>morphology, (b) predominance of <span class="Italics">Gardnerella </span>morphotype, and (c) absent or few white 	blood cells.</p>
<p>Other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, e.g., <span class="Italics">Trichomonas vaginalis</span>, <span class="Italics">Chlamydia trachomatis</span>, <span class="Italics">N. gonorrhoeae</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>, and <span class="Italics">Herpes simplex </span>virus should be ruled out.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Metronidazole Vaginal Gel is contraindicated in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive Seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity, have been reported in patients treated with oral or intravenous metronidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of metronidazole vaginal gel therapy. Metronidazole vaginal gel should be administered with caution to patients with central nervous system diseases.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reactions</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who were using oral metronidazole and disulfiram concurrently. Metronidazole vaginal gel should not be administered to patients who have taken disulfiram within the last two weeks.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<p class="First">Metronidazole Vaginal Gel affords minimal peak serum levels and systemic exposure (AUCs) of metronidazole compared to 500 mg oral metronidazole dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral metronidazole, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing metronidazole administered orally to metronidazole administered vaginally are not available.</p>
<p><span class="Bold">General:</span></p>
<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly. This results in the accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, metronidazole vaginal gel should be administered cautiously.</p>
<p>Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> may present more prominent symptoms during therapy with metronidazole vaginal gel. Approximately 6-10% of patients treated with Metronidazole Vaginal Gel developed symptomatic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> during or immediately after therapy.</p>
<p>Disulfiram-like reaction to alcohol has been reported with oral metronidazole, thus the possibility of such a reaction occurring while on metronidazole vaginal gel therapy cannot be excluded.</p>
<p>Metronidazole Vaginal Gel contains ingredients that may cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water.</p>
<p><span class="Bold">Information for the Patient:</span></p>
<p>The patient should be cautioned about drinking alcohol while being treated with metronidazole vaginal gel. While blood levels are significantly lower with Metronidazole Vaginal Gel than with usual doses of oral metronidazole, a possible interaction with alcohol cannot be excluded.</p>
<p>The patient should be instructed not to engage in vaginal intercourse during treatment with this product.</p>
<p><span class="Bold">Drug Interactions:</span></p>
<p>Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This possible drug interaction should be considered when metronidazole vaginal gel is prescribed for patients on this type of anticoagulant therapy.</p>
<p>In patients stabilized on relatively high doses of lithium, short-term oral metronidazole therapy has been associated with elevation of serum lithium levels and, in a few cases, signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
<p>Use of cimetidine with oral metronidazole may prolong the half-life and decrease plasma clearance of metronidazole.</p>
<p><span class="Bold">Drug/Laboratory Test Interactions:</span></p>
<p>Metronidazole may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide-adenine dinucleotides (NAD + NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.</p>
<p><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></p>
<p>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic oral administration in mice and rats. Prominent among the effects in the mouse was the promotion of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At very high dose levels (approximately 500 mg/kg/day), there was a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in males. Also, the published results of one of the mouse studies indicate an increase in the incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant. Several long-term oral dosing studies in the rat have been completed. There were statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered metronidazole over those noted in the concurrent female control groups. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.</p>
<p>These studies have not been conducted with 0.75% metronidazole vaginal gel, which would result in significantly lower systemic blood levels than those obtained with oral formulations.</p>
<p>Although metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro </span>assay systems, studies in mammals (<span class="Italics">in vivo</span>) have failed to demonstrate a potential for genetic damage.</p>
<p>Fertility studies have been performed in mice up to six times the recommended human oral dose (based on mg/m<span class="Sup">2</span>) and have revealed no evidence of impaired fertility.</p>
<p><span class="Bold">Pregnancy: Teratogenic Effects:</span></p>
<p>Pregnancy Category B</p>
<p>There has been no experience to date with the use of Metronidazole Vaginal Gel in pregnant patients. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed when metronidazole was administered orally to pregnant mice at six times the recommended human dose (based on mg/m<span class="Sup">2</span>); however, in a single small study where the drug was administered intraperitoneally, some intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed. The relationship of these findings to the drug is unknown.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because metronidazole is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Bold">Nursing Mothers:</span></p>
<p>Specific studies of metronidazole levels in human milk following intravaginally administered metronidazole have not been performed. However, metronidazole is secreted in human milk in concentrations similar to those found in plasma following oral administration of metronidazole.</p>
<p>Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p><span class="Bold">Pediatric Use:</span></p>
<p>Safety and effectiveness in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s7"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE EVENTS
</span></h1>
<p class="First"><span class="Bold">Clinical Trials:</span></p>
<p>There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or serious adverse events related to drug therapy in clinical trials involving 800 non-pregnant women who received Metronidazole Vaginal Gel.</p>
<p>In a randomized, single-blind clinical trial of 505 non-pregnant women who received Metronidazole Vaginal Gel once or twice a day, 2 patients (one from each regimen) discontinued therapy early due to drug-related adverse events. One patient discontinued drug because of moderate abdominal cramping and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, while the other patient discontinued drug because of mild vaginal burning. These symptoms resolved after discontinuation of drug.</p>
<p>Medical events judged to be related, probably related, or possibly related to administration of Metronidazole Vaginal Gel once or twice a day were reported for 195/505 (39%) patients. The incidence of individual adverse reactions were not significantly different between the two regimens. Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%:</p>
<p><span class="Italics">	Reproductive:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal discharge</span> (12%),</p>
<p>Symptomatic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span>/<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (10%),</p>
<p>Vulva/vaginal irritative symptoms (9%),</p>
<p>Pelvic <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (3%).</p>
<p><span class="Italics">	Gastrointestinal:</span></p>
<p>	<span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Gastrointestinal discomfort</span> (7%),</p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4%),</p>
<p>Unusual taste (2%),</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (1%),</p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> (1%),</p>
<p><span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">Abdominal bloating</span>/gas; thirsty, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">	Neurologic:</span></p>
<p>	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (5%),</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (2%),</p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>.</p>
<p><span class="Italics">Dermatologic:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Generalized itching</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Italics">	Other:</span></p>
<p>Unspecified cramping (1%),</p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>,</p>
<p>Darkened urine.</p>
<p>In previous clinical trials submitted for approved labeling of Metronidazole Vaginal Gel the following was also reported:</p>
<p><span class="Italics">	Laboratory:</span></p>
<p>Increased/decreased white blood cell counts (1.7%).</p>
<p><span class="Bold">Other Metronidazole Formulations:</span></p>
<p>Other effects that have been reported in association with the use of <span class="Bold">topical (dermal) </span>formulations of metronidazole include <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>, and mild skin dryness and burning. None of these adverse events exceeded an incidence of 2% of patients</p>
<p>Metronidazole Vaginal Gel affords minimal peak serum levels and systemic exposure (AUC) of metronidazole compared to 500 mg oral metronidazole dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral metronidazole, the possibility of these and other reactions cannot be excluded presently.</p>
<p>The following adverse reactions and altered laboratory tests have been reported with the <span class="Bold">oral or parenteral </span>use of metronidazole:</p>
<p><span class="Italics">	Cardiovascular: </span>Flattening of the T-wave may be seen in electrocardiographic tracings.</p>
<p><span class="Italics">	Central Nervous System: </span>(See <span class="Bold"><a href="#s5">WARNINGS</a></span>.) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, convulsive 	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Italics">	Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, an unpleasant metallic taste, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, 	<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, abdominal cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, â€œfurryâ€? tongue, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and 	modification of taste of alcoholic beverages.</p>
<p><span class="Italics">	Genitourinary: </span>Overgrowth of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>Â in the vagina, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>.</p>
<p><span class="Italics">	Hematopoietic: </span>Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>; erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>; dryness of the mouth, 	vagina, or vulva; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; fleeting <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span>.</p>
<p><span class="Italics">	Renal: </span><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, a sense of pelvic pressure, darkened urine.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s8"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">There is no human experience with overdosage of metronidazole vaginal gel. Vaginally applied metronidazole gel,Â  0.75% could be absorbed in sufficient amounts to produce systemic effects. (See <span class="Bold"><a href="#s5">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s9"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">The recommended dose is one applicator full of Metronidazole Vaginal Gel (approximately 5 grams containing approximately 37.5 mg of metronidazole) intravaginally once or twice a day for 5 days. For once-a-day dosing, Metronidazole Vaginal Gel should be administered at bedtime.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s10"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Metronidazole Vaginal Gel 0.75% is supplied in a 70 gram tube and packaged with 5 vaginal applicators.</p>
<p>The NDC number for the 70 gram tube is 68682-455-70.</p>
<p>Store at controlled room temperature 15Â° to 30Â°C (59Â° to 86Â°F). Protect from freezing.</p>
<p><span class="Bold">Clinical Studies</span></p>
<p>In a randomized, single-blind clinical trial of non-pregnant women with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> who received Metronidazole Vaginal Gel daily for 5 days, the clinical cure rates for evaluable patients determined at 4 weeks after completion of therapy for the QD and BID regimens were 98/185 (53%) and 109/190 (57%), respectively.</p>
<p><span class="Bold">Rx Only</span></p>
<p>Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807</p>
<p>By: DPT Laboratories, Inc., San Antonio, TX 78215</p>
<p>Rev. 11/14<br>9432501<br>140410-1114<br><br></p>
<p><br><br><span class="Bold">DIRECTIONS FOR USE</span></p>
<p><span class="Bold">1.Â  Filling the applicator</span></p>
<p>â€¢ Remove cap and puncture metal seal on tube with the pointed tip of cap. (See Figure 1)</p>
<p>â€¢ Screw end of applicator onto tube. (See Figure 2)</p>
<p>â€¢ Slowly squeeze gel out of tube and into applicator. Plunger will stop when the applicator is full. (See Figure 3)</p>
<p>â€¢ Unscrew applicator and replace cap on tube.</p>
<div class="Figure"><img alt="61eb770c-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-2.jpg"></div>
<div class="Figure"><img alt="61eb770c-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-3.jpg"></div>
<div class="Figure"><img alt="61eb770c-figure-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-4.jpg"></div>
<p><span class="Bold">2.Â  Inserting the applicator</span></p>
<p>â€¢ The applicator may be inserted while lying on your back with your knees bent or in any comfortable position.</p>
<p>â€¢ Hold filled applicator by barrel, and gently insert into vagina as far as it will comfortably go. (See Figure 4)</p>
<p>â€¢ Slowly press the plunger until it stops to deposit gel into vagina and then withdraw the applicator.</p>
<div class="Figure"><img alt="61eb770c-figure-05" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-5.jpg"></div>
<p><span class="Bold">3. Care of the applicator</span></p>
<p>If physician prescribes twice-a-day dosing:</p>
<p>â€¢ After use, pull the plunger out of the barrel. (See Figure 5)</p>
<p>â€¢ Wash both plunger and barrel in warm soapy water and rinse thoroughly.</p>
<p>â€¢ To reassemble applicator, gently push plunger back into barrel.</p>
<div class="Figure"><img alt="61eb770c-figure-06" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-6.jpg"></div>
<p><span class="Bold">IMPORTANT:</span></p>
<p>For once-a-day dosing, apply one applicator full at bedtime. For twice-a-day dosing, apply one applicator full each morning and evening for five days, or as directed by physician.</p>
<p><span class="Bold">WARNINGS:</span></p>
<p>â€¢ If significant irritation develops from the use of this medication, discontinue use and consult your physician.</p>
<p>â€¢ Do not use during pregnancy except under the supervision of a physician.</p>
<p>â€¢ Keep this and all medications out of reach of children.</p>
<p>â€¢ For vaginal use only. Not for use in the eyes, on the skin or in the mouth.</p>
<p>Store at room temperature. Avoid exposure to extreme heat or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>.</p>
<p>See end of carton and bottom of tube for lot number and expiration date.</p>
<p>Manufactured for: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807</p>
<p>By: DPT Laboratories, Inc., San Antonio, TX 78215</p>
<p>Rev. 11/14<br>9432501<br>140410-1114<br><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="PDP"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 70 gram Carton
</span></h1>
<p class="First"><span class="Bold">NDC</span> 68682-455-70</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Metronidazole Vaginal Gel, 0.75%</span><br>with 5 applicators </p>
<p><span class="Bold">FOR INTRAVAGINAL USE ONLY. (NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE.)</span></p>
<p><span class="Bold">Net Wt. 70 g</span></p>
<p>OCEANSIDE<br>PHARMACEUTICALS<span class="Sup">Â®</span></p>
<div class="Figure"><img alt="61eb770c-figure-08" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=526c226a-099b-4eb3-943d-c88b2763b2c1&amp;name=metronidazole-8.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METRONIDAZOLEÂ 		
					</strong><br><span class="contentTableReg">metronidazole gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68682-455</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">7.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER 934</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68682-455-70</td>
<td class="formItem">70 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA020208</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Oceanside Pharmaceuticals
							(832011691)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224526</td>
<td class="formItem">MANUFACTURE(68682-455)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>86b2afb2-1fa9-472e-823f-cc8a37f45340</div>
<div>Set id: 526c226a-099b-4eb3-943d-c88b2763b2c1</div>
<div>Version: 1</div>
<div>Effective Time: 20150401</div>
</div>
</div>Â <div class="DistributorName">Oceanside Pharmaceuticals</div></p>
</body></html>
